A Phase 2 Efficacy And Safety Study Of SU011248 Administered In A Continuous Daily Regimen In Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
收藏DataCite Commons2024-12-02 更新2024-07-13 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00006801/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
To evaluate the anti-tumor activity of SU011248 (sunitinib) in cytokine-refractory metastatic
renal cell carcinoma (RCC) when administered in a continuous treatment regimen
提供机构：
Vivli
创建时间：
2021-04-02
